A model using concomitant markers for predicting outcome in human papillomavirus positive oropharyngeal cancer

Human papillomavirus (HPV) was in 2007 accepted as a risk factor for oropharyngeal squamous cell carcinoma (OSCC), dominated by the tonsillar (TSCC) and base of tongue (BOTSCC) cancer subtypes [1]. Lately, the incidences of HPV-positive (HPV+) TSCC and BOTSCC have increased [2–8]. Notably, HPV+ TSCC and BOTSCC have better prognosis than corresponding HPV-negative tumors, with 80% vs. 40% disease-specific survival [9–14].

http://ift.tt/2oax1dw